Published in J Virol on March 01, 1999
Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol (2001) 8.25
Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J Virol (2004) 5.29
Structures and mechanisms of viral membrane fusion proteins: multiple variations on a common theme. Crit Rev Biochem Mol Biol (2008) 5.26
A Blueprint for HIV Vaccine Discovery. Cell Host Microbe (2012) 3.27
The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design. Microbiol Mol Biol Rev (2008) 3.16
Cryo-electron tomographic structure of an immunodeficiency virus envelope complex in situ. PLoS Pathog (2006) 2.81
The long cytoplasmic tail of gp41 is required in a cell type-dependent manner for HIV-1 envelope glycoprotein incorporation into virions. Proc Natl Acad Sci U S A (2000) 2.70
Crystal structure of HIV-1 gp41 including both fusion peptide and membrane proximal external regions. PLoS Pathog (2010) 2.33
Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma. J Virol (2006) 2.33
Genetic evidence for an interaction between human immunodeficiency virus type 1 matrix and alpha-helix 2 of the gp41 cytoplasmic tail. J Virol (2000) 2.27
HIV-1 envelope glycoprotein biosynthesis, trafficking, and incorporation. J Mol Biol (2011) 2.01
Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5. J Virol (2001) 1.99
A replication-competent, neutralization-sensitive variant of simian immunodeficiency virus lacking 100 amino acids of envelope. J Virol (2002) 1.97
The membrane-proximal stem region of vesicular stomatitis virus G protein confers efficient virus assembly. J Virol (2000) 1.96
Role of the membrane-proximal domain in the initial stages of human immunodeficiency virus type 1 envelope glycoprotein-mediated membrane fusion. J Virol (1999) 1.89
Broadly neutralizing anti-HIV-1 antibodies disrupt a hinge-related function of gp41 at the membrane interface. Proc Natl Acad Sci U S A (2009) 1.79
Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external region. J Virol (2009) 1.78
Relationship between antibody 2F5 neutralization of HIV-1 and hydrophobicity of its heavy chain third complementarity-determining region. J Virol (2009) 1.70
Nef increases the synthesis of and transports cholesterol to lipid rafts and HIV-1 progeny virions. Proc Natl Acad Sci U S A (2003) 1.69
Aromatic residues at the edge of the antibody combining site facilitate viral glycoprotein recognition through membrane interactions. Proc Natl Acad Sci U S A (2010) 1.64
A conformational switch in human immunodeficiency virus gp41 revealed by the structures of overlapping epitopes recognized by neutralizing antibodies. J Virol (2009) 1.63
Sequential roles of receptor binding and low pH in forming prehairpin and hairpin conformations of a retroviral envelope glycoprotein. J Virol (2004) 1.62
Membrane interface-interacting sequences within the ectodomain of the human immunodeficiency virus type 1 envelope glycoprotein: putative role during viral fusion. J Virol (2000) 1.58
Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1. Cold Spring Harb Perspect Med (2011) 1.58
In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10. J Virol (2007) 1.56
The influenza virus ion channel and maturation cofactor M2 is a cholesterol-binding protein. Eur Biophys J (2004) 1.54
Lipids and membrane microdomains in HIV-1 replication. Virus Res (2009) 1.51
Structural insights into key sites of vulnerability on HIV-1 Env and influenza HA. Immunol Rev (2012) 1.44
Importance of the membrane-perturbing properties of the membrane-proximal external region of human immunodeficiency virus type 1 gp41 to viral fusion. J Virol (2008) 1.40
Juxtamembrane protein segments that contribute to recruitment of cholesterol into domains. Biochemistry (2006) 1.36
The membrane-proximal domain of vesicular stomatitis virus G protein functions as a membrane fusion potentiator and can induce hemifusion. J Virol (2002) 1.32
Direct evidence that C-peptide inhibitors of human immunodeficiency virus type 1 entry bind to the gp41 N-helical domain in receptor-activated viral envelope. J Virol (2003) 1.30
Antibody mechanics on a membrane-bound HIV segment essential for GP41-targeted viral neutralization. Nat Struct Mol Biol (2011) 1.29
Analysis of the human immunodeficiency virus type 1 gp41 membrane proximal external region arrayed on hepatitis B surface antigen particles. Virology (2007) 1.29
Role of the membrane-spanning domain of human immunodeficiency virus type 1 envelope glycoprotein in cell-cell fusion and virus infection. J Virol (2008) 1.28
4E10-resistant variants in a human immunodeficiency virus type 1 subtype C-infected individual with an anti-membrane-proximal external region-neutralizing antibody response. J Virol (2007) 1.26
Broad neutralization of human immunodeficiency virus type 1 (HIV-1) elicited from human rhinoviruses that display the HIV-1 gp41 ELDKWA epitope. J Virol (2009) 1.21
Structure of the HIV-1 gp41 membrane-proximal ectodomain region in a putative prefusion conformation. Biochemistry (2009) 1.20
Anti-gp41 antibodies cloned from HIV-infected patients with broadly neutralizing serologic activity. J Virol (2010) 1.17
Induction of antibodies in rhesus macaques that recognize a fusion-intermediate conformation of HIV-1 gp41. PLoS One (2011) 1.15
Latent infection membrane protein transmembrane FWLY is critical for intermolecular interaction, raft localization, and signaling. Proc Natl Acad Sci U S A (2003) 1.14
The membrane-proximal region of vesicular stomatitis virus glycoprotein G ectodomain is critical for fusion and virus infectivity. J Virol (2003) 1.13
HIV envelope: challenges and opportunities for development of entry inhibitors. Trends Microbiol (2011) 1.13
Immunogenicity of recombinant human immunodeficiency virus type 1-like particles expressing gp41 derivatives in a pre-fusion state. Vaccine (2006) 1.12
Structural and functional roles of HIV-1 gp41 pretransmembrane sequence segmentation. Biophys J (2003) 1.11
Structure-function studies of the self-assembly domain of the human immunodeficiency virus type 1 transmembrane protein gp41. J Virol (2000) 1.10
Crystallographic definition of the epitope promiscuity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5: vaccine design implications. J Virol (2009) 1.09
Functional implications of the human T-lymphotropic virus type 1 transmembrane glycoprotein helical hairpin structure. J Virol (2000) 1.08
Neutralizing epitopes in the membrane-proximal external region of HIV-1 gp41 are influenced by the transmembrane domain and the plasma membrane. J Virol (2012) 1.08
The broadly neutralizing anti-human immunodeficiency virus type 1 4E10 monoclonal antibody is better adapted to membrane-bound epitope recognition and blocking than 2F5. J Virol (2008) 1.08
Role of lipids in virus replication. Cold Spring Harb Perspect Biol (2011) 1.08
Role of the ectodomain of the gp41 transmembrane envelope protein of human immunodeficiency virus type 1 in late steps of the membrane fusion process. J Virol (2004) 1.07
Assessment of antibody responses against gp41 in HIV-1-infected patients using soluble gp41 fusion proteins and peptides derived from M group consensus envelope. Virology (2007) 1.07
Capturing a fusion intermediate of influenza hemagglutinin with a cholesterol-conjugated peptide, a new antiviral strategy for influenza virus. J Biol Chem (2011) 1.06
Induction of HIV neutralizing antibodies against the MPER of the HIV envelope protein by HA/gp41 chimeric protein-based DNA and VLP vaccines. PLoS One (2011) 1.06
Structure of an HIV-1-neutralizing antibody target, the lipid-bound gp41 envelope membrane proximal region trimer. Proc Natl Acad Sci U S A (2014) 1.01
Wild-type-like viral replication potential of human immunodeficiency virus type 1 envelope mutants lacking palmitoylation signals. J Virol (2005) 1.01
Role of HIV Gp41 mediated fusion/hemifusion in bystander apoptosis. Cell Mol Life Sci (2008) 1.00
Mutagenesis of tyrosine and di-leucine motifs in the HIV-1 envelope cytoplasmic domain results in a loss of Env-mediated fusion and infectivity. Retrovirology (2011) 1.00
Role of lipid structure in the humoral immune response in mice to covalent lipid-peptides from the membrane proximal region of HIV-1 gp41. Vaccine (2009) 1.00
A tyrosine motif in the cytoplasmic domain of mason-pfizer monkey virus is essential for the incorporation of glycoprotein into virions. J Virol (2003) 0.99
The membrane proximal external region of the HIV-1 envelope glycoprotein gp41 contributes to the stabilization of the six-helix bundle formed with a matching N' peptide. Biochemistry (2008) 0.98
Structural and Thermodynamic Basis of Epitope Binding by Neutralizing and Nonneutralizing Forms of the Anti-HIV-1 Antibody 4E10. J Virol (2015) 0.96
Important role for the transmembrane domain of severe acute respiratory syndrome coronavirus spike protein during entry. J Virol (2006) 0.95
Envelope proteins containing single amino acid substitutions support a structural model of the receptor-binding domain of bovine leukemia virus surface protein. J Virol (2002) 0.95
The Atomic Structure of the HIV-1 gp41 Transmembrane Domain and Its Connection to the Immunogenic Membrane-proximal External Region. J Biol Chem (2015) 0.94
The pre-transmembrane domain of the Autographa californica multicapsid nucleopolyhedrovirus GP64 protein is critical for membrane fusion and virus infectivity. J Virol (2009) 0.94
Hairpin folding of HIV gp41 abrogates lipid mixing function at physiologic pH and inhibits lipid mixing by exposed gp41 constructs. Biochemistry (2009) 0.93
Immunogenicity of membrane-bound HIV-1 gp41 membrane-proximal external region (MPER) segments is dominated by residue accessibility and modulated by stereochemistry. J Biol Chem (2013) 0.93
C-terminal tail of human immunodeficiency virus gp41: functionally rich and structurally enigmatic. J Gen Virol (2012) 0.93
Insights into the mechanism of HIV-1 envelope induced membrane fusion as revealed by its inhibitory peptides. Eur Biophys J (2011) 0.93
Mechanism of inhibition of enveloped virus membrane fusion by the antiviral drug arbidol. PLoS One (2011) 0.93
Resistance profiles of novel electrostatically constrained HIV-1 fusion inhibitors. J Biol Chem (2010) 0.92
In silico vaccine design based on molecular simulations of rhinovirus chimeras presenting HIV-1 gp41 epitopes. J Mol Biol (2008) 0.91
HIV-1 envelope glycoprotein-mediated fusion and pathogenesis: implications for therapy and vaccine development. Vaccine (2008) 0.91
Antiviral activity and conformational features of an octapeptide derived from the membrane-proximal ectodomain of the feline immunodeficiency virus transmembrane glycoprotein. J Virol (2003) 0.91
Structural basis for HIV-1 neutralization by 2F5-like antibodies m66 and m66.6. J Virol (2013) 0.91
4E10-resistant HIV-1 isolated from four subjects with rare membrane-proximal external region polymorphisms. PLoS One (2010) 0.91
Cloaked similarity between HIV-1 and SARS-CoV suggests an anti-SARS strategy. BMC Microbiol (2003) 0.91
A peptide pertaining to the loop segment of human immunodeficiency virus gp41 binds and interacts with model biomembranes: implications for the fusion mechanism. J Virol (2005) 0.91
CRAC motif peptide of the HIV-1 gp41 protein thins SOPC membranes and interacts with cholesterol. Biochim Biophys Acta (2008) 0.90
Functional stability of unliganded envelope glycoprotein spikes among isolates of human immunodeficiency virus type 1 (HIV-1). PLoS One (2011) 0.90
Human Ubc9 contributes to production of fully infectious human immunodeficiency virus type 1 virions. J Virol (2009) 0.90
Receptor-triggered but alkylation-arrested env of murine leukemia virus reveals the transmembrane subunit in a prehairpin conformation. J Virol (2006) 0.89
Canine distemper virus and measles virus fusion glycoprotein trimers: partial membrane-proximal ectodomain cleavage enhances function. J Virol (2004) 0.89
Complementation of diverse HIV-1 Env defects through cooperative subunit interactions: a general property of the functional trimer. Retrovirology (2009) 0.88
Erythrocyte Binding Activity Displayed by a Selective Group of Plasmodium vivax Tryptophan Rich Antigens Is Inhibited by Patients' Antibodies. PLoS One (2012) 0.88
Functional characterization of heptad repeat 1 and 2 mutants of the spike protein of severe acute respiratory syndrome coronavirus. J Virol (2006) 0.88
The three lives of viral fusion peptides. Chem Phys Lipids (2014) 0.87
Identification of the LWYIK motif located in the human immunodeficiency virus type 1 transmembrane gp41 protein as a distinct determinant for viral infection. J Virol (2008) 0.87
Peptide P5 (residues 628-683), comprising the entire membrane proximal region of HIV-1 gp41 and its calcium-binding site, is a potent inhibitor of HIV-1 infection. Retrovirology (2008) 0.87
Effect of epitope position on neutralization by anti-human immunodeficiency virus monoclonal antibody 2F5. J Virol (2006) 0.86
Role of chirality in peptide-induced formation of cholesterol-rich domains. Biochem J (2005) 0.86
Disruption of helix-capping residues 671 and 674 reveals a role in HIV-1 entry for a specialized hinge segment of the membrane proximal external region of gp41. J Mol Biol (2013) 0.86
Plasmodium vivax tryptophan-rich antigen PvTRAg33.5 contains alpha helical structure and multidomain architecture. PLoS One (2011) 0.86
High-efficiency transformation of mammalian cells by plasmid DNA. Mol Cell Biol (1987) 43.61
HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science (1996) 26.19
Atomic structure of the ectodomain from HIV-1 gp41. Nature (1997) 16.31
Core structure of gp41 from the HIV envelope glycoprotein. Cell (1997) 16.18
Structure of influenza haemagglutinin at the pH of membrane fusion. Nature (1994) 14.61
Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene. J Virol (1992) 12.89
A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol (1993) 10.75
pH-independent HIV entry into CD4-positive T cells via virus envelope fusion to the plasma membrane. Cell (1987) 9.29
Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding. J Exp Med (1991) 9.28
Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci U S A (1994) 8.48
Virus entry into animal cells. Adv Virus Res (1989) 7.78
Rapid complementation assays measuring replicative potential of human immunodeficiency virus type 1 envelope glycoprotein mutants. J Virol (1990) 6.54
A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. Proc Natl Acad Sci U S A (1992) 5.88
Lipid-anchored influenza hemagglutinin promotes hemifusion, not complete fusion. Cell (1994) 5.65
HIV-1 inhibition by a peptide. Nature (1993) 5.01
Detection of a fusion peptide sequence in the transmembrane protein of human immunodeficiency virus. Cell (1987) 4.84
Characterization of the fusion domain of the human immunodeficiency virus type 1 envelope glycoprotein gp41. Proc Natl Acad Sci U S A (1990) 4.64
Folding and assembly of viral membrane proteins. Virology (1993) 4.63
Conformational changes induced in the envelope glycoproteins of the human and simian immunodeficiency viruses by soluble receptor binding. J Virol (1993) 4.22
Truncation of the human immunodeficiency virus type 1 transmembrane glycoprotein cytoplasmic domain blocks virus infectivity. J Virol (1992) 4.20
Effects of amino acid changes in the extracellular domain of the human immunodeficiency virus type 1 gp41 envelope glycoprotein. J Virol (1993) 4.19
Human immunodeficiency virus infection of CD4-bearing cells occurs by a pH-independent mechanism. EMBO J (1988) 3.98
Identification of the fusion peptide of primate immunodeficiency viruses. Science (1989) 3.83
Effects of deletions in the cytoplasmic domain on biological functions of human immunodeficiency virus type 1 envelope glycoproteins. J Virol (1992) 3.82
Membrane fusion mediated by the influenza virus hemagglutinin requires the concerted action of at least three hemagglutinin trimers. J Cell Biol (1996) 3.77
The pH independence of mammalian retrovirus infection. J Gen Virol (1990) 3.68
Structure of detergent-resistant membrane domains: does phase separation occur in biological membranes? Biochem Biophys Res Commun (1997) 3.67
Mutations in the leucine zipper of the human immunodeficiency virus type 1 transmembrane glycoprotein affect fusion and infectivity. J Virol (1992) 3.54
Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS. J Virol (1994) 3.49
Polarized apical distribution of glycosyl-phosphatidylinositol-anchored proteins in a renal epithelial cell line. Proc Natl Acad Sci U S A (1988) 3.19
Epitope exposure on functional, oligomeric HIV-1 gp41 molecules. Virology (1995) 3.06
Changes in the transmembrane region of the human immunodeficiency virus type 1 gp41 envelope glycoprotein affect membrane fusion. J Virol (1990) 2.95
Retained in vitro infectivity and cytopathogenicity of HIV-1 despite truncation of the C-terminal tail of the env gene product. Virology (1992) 2.89
Propensity for a leucine zipper-like domain of human immunodeficiency virus type 1 gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the glycoprotein complex. Proc Natl Acad Sci U S A (1994) 2.88
Mutations in the cytoplasmic domain of human immunodeficiency virus type 1 transmembrane protein impair the incorporation of Env proteins into mature virions. J Virol (1993) 2.80
Mutational analysis of the leucine zipper-like motif of the human immunodeficiency virus type 1 envelope transmembrane glycoprotein. J Virol (1993) 2.21
The ectodomain of HIV-1 env subunit gp41 forms a soluble, alpha-helical, rod-like oligomer in the absence of gp120 and the N-terminal fusion peptide. EMBO J (1996) 2.21
Receptor-induced conformational changes in the subgroup A avian leukosis and sarcoma virus envelope glycoprotein. J Virol (1995) 2.10
The role of CD4 in HIV binding and entry. Philos Trans R Soc Lond B Biol Sci (1993) 1.99
Retention and retrieval in the endoplasmic reticulum and the Golgi apparatus. Curr Opin Cell Biol (1994) 1.99
Mutations in the membrane-spanning domain of the human immunodeficiency virus envelope glycoprotein that affect fusion activity. J Virol (1994) 1.93
The inhibitory activity of an HIV type 1 peptide correlates with its ability to interact with a leucine zipper structure. AIDS Res Hum Retroviruses (1995) 1.77
Alpha-helical, but not beta-sheet, propensity of proline is determined by peptide environment. Proc Natl Acad Sci U S A (1996) 1.67
Functional role of the zipper motif region of human immunodeficiency virus type 1 transmembrane protein gp41. J Virol (1994) 1.61
Mutational analysis of the leucine zipper motif in the Newcastle disease virus fusion protein. J Virol (1995) 1.59
Analysis of the cleavage site of the human immunodeficiency virus type 1 glycoprotein: requirement of precursor cleavage for glycoprotein incorporation. J Virol (1995) 1.54
Identification of membrane anchorage domains of the HIV-1 gp160 envelope glycoprotein precursor. J Acquir Immune Defic Syndr (1991) 1.53
Low-pH induced conformational changes in viral fusion proteins: implications for the fusion mechanism. J Gen Virol (1995) 1.50
Expression and characterization of glycophospholipid-anchored human immunodeficiency virus type 1 envelope glycoproteins. J Virol (1993) 1.47
Assembly of a rod-shaped chimera of a trimeric GCN4 zipper and the HIV-1 gp41 ectodomain expressed in Escherichia coli. Proc Natl Acad Sci U S A (1997) 1.35
Mutational analysis of conserved N-linked glycosylation sites of human immunodeficiency virus type 1 gp41. J Virol (1992) 1.35
Lipid membrane fusion induced by the human immunodeficiency virus type 1 gp41 N-terminal extremity is determined by its orientation in the lipid bilayer. J Virol (1996) 1.32
Determinants of human immunodeficiency virus type 1 envelope glycoprotein oligomeric structure. J Virol (1995) 1.19
Influence of tryptophan residues on melittin's hemolytic activity. Biochim Biophys Acta (1993) 1.14
Role of the fusogenic peptide sequence in syncytium induction and infectivity of human immunodeficiency virus type 2. J Virol (1992) 1.11
Retention of the human immunodeficiency virus type 1 envelope glycoprotein in the endoplasmic reticulum does not redirect virus assembly from the plasma membrane. J Virol (1998) 1.05
Protein conformational changes in virus-cell fusion. Methods Enzymol (1993) 0.99
Cholesterol as a target for toxins. Biosci Rep (1990) 0.91
Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med (1998) 8.62
Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol (2000) 6.71
Nucleotide sequence of Mason-Pfizer monkey virus: an immunosuppressive D-type retrovirus. Cell (1986) 6.07
Myristylation is required for intracellular transport but not for assembly of D-type retrovirus capsids. J Virol (1987) 5.68
A small element from the Mason-Pfizer monkey virus genome makes human immunodeficiency virus type 1 expression and replication Rev-independent. Proc Natl Acad Sci U S A (1994) 4.43
Truncation of the human immunodeficiency virus type 1 transmembrane glycoprotein cytoplasmic domain blocks virus infectivity. J Virol (1992) 4.20
A single amino acid substitution within the matrix protein of a type D retrovirus converts its morphogenesis to that of a type C retrovirus. Cell (1990) 3.70
A proline-rich motif (PPPY) in the Gag polyprotein of Mason-Pfizer monkey virus plays a maturation-independent role in virion release. J Virol (1998) 3.69
Mutations in the leucine zipper of the human immunodeficiency virus type 1 transmembrane glycoprotein affect fusion and infectivity. J Virol (1992) 3.54
Mutants of the Rous sarcoma virus envelope glycoprotein that lack the transmembrane anchor and cytoplasmic domains: analysis of intracellular transport and assembly into virions. J Virol (1987) 3.28
Human immunodeficiency virus envelope protein determines the site of virus release in polarized epithelial cells. Proc Natl Acad Sci U S A (1991) 3.18
Mutations of the Rous sarcoma virus env gene that affect the transport and subcellular location of the glycoprotein products. J Cell Biol (1984) 3.11
Oligomeric structure of a prototype retrovirus glycoprotein. Proc Natl Acad Sci U S A (1988) 3.06
Propensity for a leucine zipper-like domain of human immunodeficiency virus type 1 gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the glycoprotein complex. Proc Natl Acad Sci U S A (1994) 2.88
Mutational analysis of the major homology region of Mason-Pfizer monkey virus by use of saturation mutagenesis. J Virol (1992) 2.56
Complete sequence of the Rous sarcoma virus env gene: identification of structural and functional regions of its product. J Virol (1983) 2.53
Preassembled capsids of type D retroviruses contain a signal sufficient for targeting specifically to the plasma membrane. J Virol (1990) 2.51
Amino acid substitutions within the matrix protein of type D retroviruses affect assembly, transport and membrane association of a capsid. EMBO J (1991) 2.51
Amino acids encoded downstream of gag are not required by Rous sarcoma virus protease during gag-mediated assembly. J Virol (1991) 2.38
Structural role of the matrix protein of type D retroviruses in gag polyprotein stability and capsid assembly. J Virol (1990) 2.34
Functional RT and IN incorporated into HIV-1 particles independently of the Gag/Pol precursor protein. EMBO J (1997) 2.23
Mutations within the proteolytic cleavage site of the Rous sarcoma virus glycoprotein that block processing to gp85 and gp37. J Virol (1987) 2.07
Factors associated with HIV prevalence in a pre-partum cohort of Zambian women. Int J STD AIDS (2006) 2.02
Truncations of the simian immunodeficiency virus transmembrane protein confer expanded virus host range by removing a block to virus entry into cells. J Virol (1993) 1.99
Postassembly cleavage of a retroviral glycoprotein cytoplasmic domain removes a necessary incorporation signal and activates fusion activity. J Virol (1994) 1.97
Role of the membrane-proximal domain in the initial stages of human immunodeficiency virus type 1 envelope glycoprotein-mediated membrane fusion. J Virol (1999) 1.89
Synthesis and assembly of retrovirus Gag precursors into immature capsids in vitro. J Virol (1996) 1.85
Polypeptides of Mason-Pfizer monkey virus. I. Synthesis and processing of the gag-gene products. Virology (1984) 1.83
A viral protease-mediated cleavage of the transmembrane glycoprotein of Mason-Pfizer monkey virus can be suppressed by mutations within the matrix protein. Proc Natl Acad Sci U S A (1992) 1.83
Efficient in vivo and in vitro assembly of retroviral capsids from Gag precursor proteins expressed in bacteria. J Virol (1995) 1.81
A chimeric avian retrovirus containing the influenza virus hemagglutinin gene has an expanded host range. J Virol (1992) 1.80
Distinct subsets of retroviruses encode dUTPase. J Virol (1992) 1.80
Avian reticuloendotheliosis viruses: evolutionary linkage with mammalian type C retroviruses. J Virol (1979) 1.68
The mechanism for genetic recombination in the avian retroviruses. Curr Top Microbiol Immunol (1978) 1.67
Biological techniques for avian sarcoma viruses. Methods Enzymol (1979) 1.67
Analysis of the cleavage site of the human immunodeficiency virus type 1 glycoprotein: requirement of precursor cleavage for glycoprotein incorporation. J Virol (1995) 1.54
A charged amino acid substitution within the transmembrane anchor of the Rous sarcoma virus envelope glycoprotein affects surface expression but not intracellular transport. J Cell Biol (1987) 1.50
Mutations within the proteolytic cleavage site of the Rous sarcoma virus glycoprotein define a requirement for dibasic residues for intracellular cleavage. J Virol (1992) 1.50
Expression and characterization of glycophospholipid-anchored human immunodeficiency virus type 1 envelope glycoproteins. J Virol (1993) 1.47
Effect of retroviral proteinase inhibitors on Mason-Pfizer monkey virus maturation and transmembrane glycoprotein cleavage. J Virol (1992) 1.46
Amino-terminal amino acid sequence of the major structural polypeptides of avian retroviruses: sequence homology between reticuloendotheliosis virus p30 and p30s of mammalian retroviruses. Proc Natl Acad Sci U S A (1978) 1.46
AIDS biosafety. Science (1991) 1.44
Pausing of reverse transcriptase on retroviral RNA templates is influenced by secondary structures both 5' and 3' of the catalytic site. Nucleic Acids Res (1998) 1.43
Inhibition of Rous sarcoma virus replication by 2-deoxyglucose and tunicamycin: identification of an unglycosylated env gene product. J Virol (1979) 1.42
Oligomerization of the hydrophobic heptad repeat of gp41. J Virol (1995) 1.38
Functional analysis of the core human immunodeficiency virus type 1 packaging signal in a permissive cell line. J Virol (1998) 1.38
Effect of cloned human interferons on protein synthesis and morphogenesis of herpes simplex virus. J Virol (1985) 1.38
Human immunodeficiency virus type 1 envelope glycoprotein is modified by O-linked oligosaccharides. J Virol (1994) 1.35
V3 loop region of the HIV-1 gp120 envelope protein is essential for virus infectivity. Virology (1992) 1.35
Identification of a cytoplasmic targeting/retention signal in a retroviral Gag polyprotein. J Virol (1999) 1.33
An avian sarcoma virus mutant that is temperature sensitive for virion assembly. Virology (1976) 1.33
Alterations in the transport and processing of Rous sarcoma virus envelope glycoproteins mutated in the signal and anchor regions. J Cell Biochem (1983) 1.31
Type D retrovirus capsid assembly and release are active events requiring ATP. J Virol (1998) 1.22
Amino-terminal deletion mutants of the Rous sarcoma virus glycoprotein do not block signal peptide cleavage but can block intracellular transport. J Cell Biol (1986) 1.21
Mutational analysis of conserved domains within the cytoplasmic tail of gp41 from human immunodeficiency virus type 1: effects on glycoprotein incorporation and infectivity. J Virol (2000) 1.21
Molecular cloning of the wild-type phoM operon in Escherichia coli K-12. J Bacteriol (1988) 1.20
Epidemiological characteristics of human herpesvirus-8 infection in a large population of antenatal women in Zambia. J Med Virol (2005) 1.19
A rapid screening procedure for the isolation of nonconditional replication mutants of Mason-Pfizer monkey virus: identification of a mutant defective in pol. Virology (1985) 1.19
Importance of p12 protein in Mason-Pfizer monkey virus assembly and infectivity. J Virol (1992) 1.19
Expression of the Rous sarcoma virus env gene from a simian virus 40 late-region replacement vector: effects of upstream initiation codons. J Virol (1987) 1.18
Alignment of the peptides derived from acid-catalyzed cleavage of an aspartylprolyl bond in the major internal structural polypeptide of avian retroviruses. J Biol Chem (1980) 1.17
Molecular events in the assembly of retrovirus particles. Adv Exp Med Biol (1998) 1.16
T lymphocyte cytotoxicity with natural varicella-zoster virus infection and after immunization with live attenuated varicella vaccine. J Immunol (1989) 1.15
Type D retrovirus Gag polyprotein interacts with the cytosolic chaperonin TRiC. J Virol (2001) 1.14
Separate assembly and transport domains within the Gag precursor of Mason-Pfizer monkey virus. J Virol (1999) 1.13
Can otolith elemental chemistry retrospectively track migrations in fully marine fishes? J Fish Biol (2012) 1.12
Mutations within the env gene of Mason-Pfizer monkey virus: effects on protein transport and SU-TM association. J Virol (1992) 1.12
Immunodeficiency in rhesus monkeys associated with the original Mason-Pfizer monkey virus. J Natl Cancer Inst (1986) 1.11
Health-related behaviours as predictors of mortality and morbidity in Australian Aborigines. Prev Med (2006) 1.09
Palmitoylation of the Rous sarcoma virus transmembrane glycoprotein is required for protein stability and virus infectivity. J Virol (2001) 1.09
Secondary structure model of the Mason-Pfizer monkey virus 5' leader sequence: identification of a structural motif common to a variety of retroviruses. J Virol (1995) 1.09
Polypeptides of Mason-Pfizer monkey virus. II. Synthesis and processing of the env gene products. Virology (1986) 1.09
Production and purification of a recombinant elastomeric polypeptide, G-(VPGVG)19-VPGV, from Escherichia coli. Biotechnol Prog (1992) 1.08
Inhibition of avian sarcoma virus replication by glucosamine. Virology (1974) 1.08
Molecular cloning of the Mason-Pfizer monkey virus genome: characterization and cloning of subgenomic fragments. Virology (1985) 1.08
Analysis of Mason-Pfizer monkey virus Gag particles by scanning transmission electron microscopy. J Virol (2001) 1.07
Social-cultural aspects of epilepsy in Kilimanjaro Region, Tanzania: knowledge and experience among patients and carers. Epilepsy Behav (2011) 1.07
Interferon inhibits Sendai virus-induced cell fusion: an effect on cell membrane fluidity. Proc Natl Acad Sci U S A (1982) 1.07
Tracheostomy in thermally injured patients: a review of five years' experience. Am Surg (1972) 1.06
Transport of membrane proteins to the cell surface. Curr Top Microbiol Immunol (1991) 1.06
Analysis of retroviral assembly using a vaccinia/T7-polymerase complementation system. Virology (1993) 1.06
Analysis of Mason-Pfizer monkey virus Gag domains required for capsid assembly in bacteria: role of the N-terminal proline residue of CA in directing particle shape. J Virol (2000) 1.06
Retention of the human immunodeficiency virus type 1 envelope glycoprotein in the endoplasmic reticulum does not redirect virus assembly from the plasma membrane. J Virol (1998) 1.05
Amino-terminal amino acid sequence of p10, the fifth major gag polypeptide of avian sarcoma and leukemia viruses. J Virol (1983) 1.04
Polypeptides of Mason-Pfizer monkey virus. III. Translational order of proteins on the gag and env gene specified precursor polypeptides. Virology (1986) 1.03
Effect of monensin on Mason-Pfizer monkey virus glycoprotein synthesis. J Virol (1982) 1.02
Three active forms of aspartic proteinase from Mason-Pfizer monkey virus. Virology (1998) 1.01
Mutations within the transmembrane glycoprotein of Mason-Pfizer monkey virus: loss of SU-TM association and effects on infectivity. Virology (1994) 1.01
Inhibition of avian sarcoma virus replication by glucosamine: a specific effect on the synthesis and processing of viral proteins. Virology (1976) 1.00
Calmodulin and HIV type 1: interactions with Gag and Gag products. AIDS Res Hum Retroviruses (2000) 1.00
Integration of ambulance staff trained in cardiopulmonary resuscitation with a medical team providing prehospital coronary care. Br Heart J (1989) 0.99
Expression of simian type D retroviral (Mason-Pfizer monkey virus) capsids in insect cells using recombinant baculovirus. Virology (1993) 0.98
Haemoglobin sydney: Beta-67 (E11) valine modified to alanine: an emerging pattern of unstable haemoglobins. Nature (1967) 0.98
Domains in the simian immunodeficiency virus gp41 cytoplasmic tail required for envelope incorporation into particles. Virology (2001) 0.97